EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
about
Mesothelin-Targeted CARs: Driving T Cells to Solid TumorsThe progress of immunotherapy for glioblastomaBiomarkers for glioma immunotherapy: the next generationEGFR Amplification and Glioblastoma Stem-Like CellsPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsAre BiTEs the "missing link" in cancer therapy?Smart CARs engineered for cancer immunotherapyImmunocompetent murine models for the study of glioblastoma immunotherapyTumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Antibody-based immunotherapy for malignant glioma.Epidermal growth factor receptor and variant III targeted immunotherapy.Immunotherapy for malignant gliomaEGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastomaCAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastomaDual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.Emerging immunotherapies for glioblastomaPrioritization schema for immunotherapy clinical trials in glioblastoma.Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.Advances in Immunotherapy for Glioblastoma Multiforme.Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.ErbB-targeted CAR T-cell immunotherapy of cancer.Glioblastoma antigen discovery--foundations for immunotherapy.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.CAR T-cell immunotherapy: The path from the by-road to the freeway?Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).Advances in the molecular genetics of gliomas - implications for classification and therapy.Driving gene-engineered T cell immunotherapy of cancer.Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells.Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.Engineered T cells: the promise and challenges of cancer immunotherapy.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.Developing immunotherapeutic strategies to target brain tumors.
P2860
Q26778759-23B9781D-1B38-4A35-B912-E8EDDAF1867AQ26797282-E7A0243D-CD0B-4D76-BC4C-8FF5B33FC016Q26825496-01796C0B-DA03-4AAF-B962-3CE7C78CB20AQ26853549-1CB4EF5B-3E79-44C7-8C87-A0DD9C27411FQ27339832-04D73BA3-1E02-4CAD-BF57-07635D397328Q28083907-C9DE64AB-6C9C-40A6-96BB-6237F56ADDC7Q28087236-C372B532-1E5A-41C8-8E31-186A217E0B72Q33574853-63480B09-1709-4393-BF2A-9BB5DBBEBF6DQ33689478-2FAD303F-886D-4185-BD0E-5ADC9CBF18EBQ33795137-5C2CC15F-0418-4248-9E5F-E4BBAC3D0A4AQ34120472-7B98D407-FD8C-4A54-9521-27DE72D63E39Q34391942-2F481FAC-65AA-4E9B-A148-B015984D3037Q35114086-CA6FDD14-2C2F-4E1E-BBA6-FEA4A94F506CQ35145144-CE971A53-FC24-49EC-B3D0-2410C10BAFB6Q35162266-1AD9FDE3-44F1-4B45-95A4-249393EA60ECQ35597405-B3FFF736-D3FA-4ED0-8BFF-01DF04D04F53Q35741739-768FDC00-6ACE-4820-846E-B670B9BA1BC7Q35834087-F1918AB2-B49F-40CB-B1CA-C3334F0041CEQ35877585-DA3ADA01-BB60-4ED8-B067-873FED64B8C9Q36248008-B21CDA19-2E43-4DBD-AE88-064A7755AB99Q36474226-F7556F01-84CA-49DA-B491-5FB2E32473FDQ36821054-9E8F996F-AED4-4C07-87A0-68B900951D58Q37025105-3699BF37-3D1F-484D-A915-23897862C0B8Q37078999-9EFCE24B-6617-4E48-B22F-7F529AC7DF1CQ37520179-5C374616-7634-47F1-86B4-D2CE354DBA33Q37680966-9C9590DF-BC80-45BB-A10B-50780E814E99Q38245925-4D881EC3-BEEF-48E5-AA72-7A6DB49426E0Q38362051-3A7B3994-9196-40A3-BC97-E3AD73B33741Q38389298-A97B30BF-D646-4DDA-8ECF-6D26EFF1AE40Q38516823-181697EF-68FB-4CBA-B0FE-8715C4AC31B3Q38583655-4DDC7B5C-0026-4539-B0AC-E714E77EA5ADQ38632105-563172BA-ABDC-4252-B70F-147C15FFA1C9Q38681083-FB4517A6-A53A-4D1C-A4CA-D11B30320064Q38777058-E6239DDB-9A02-4A43-84F5-DAF533941843Q38777742-10A6A56B-DDF1-4D45-B2B4-0A26AB5EE849Q38805749-6A35D9A9-37B1-4915-8126-21EF54D3FE84Q38823847-42A78990-FE72-4795-93DE-70AC8F78A8F2Q38828829-83C7D5D0-32AB-4D99-8A89-91CB932AA563Q38845812-39C2AD86-1476-4D0F-8438-29DAA7024068Q38851464-97880931-F8E6-4DE7-A157-FA6CB65261B9
P2860
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EGFRvIII mCAR-modified T-cell ...... ty against tumor-antigen loss.
@en
EGFRvIII mCAR-modified T-cell ...... ty against tumor-antigen loss.
@nl
type
label
EGFRvIII mCAR-modified T-cell ...... ty against tumor-antigen loss.
@en
EGFRvIII mCAR-modified T-cell ...... ty against tumor-antigen loss.
@nl
prefLabel
EGFRvIII mCAR-modified T-cell ...... ty against tumor-antigen loss.
@en
EGFRvIII mCAR-modified T-cell ...... ty against tumor-antigen loss.
@nl
P2093
P2860
P1476
EGFRvIII mCAR-modified T-cell ...... ity against tumor-antigen loss
@en
P2093
Bryan D Choi
Carter M Suryadevara
Catherine T Flores
Chien-Tsun Kuan
David J Snyder
Elizabeth A Reap
James E Herndon
Laura A Johnson
Luis Sanchez-Perez
Pamela K Norberg
P2860
P304
P356
10.1158/1078-0432.CCR-13-0709
P407
P50
P577
2013-12-18T00:00:00Z